drugset

drugset / Trial / NCT00151931

Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis

NCT00151931 ↗

Phase 3 Completed 456 enrolled Shire

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with lanthanum carbonate

Timeline

Start: 2004-05-11
Primary completion: 2006-01-12
Completion: 2006-01-12

Publications

Background Hutchison AJ, Laville M; SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008 Nov;23(11):3677-84. doi: 10.1093/ndt/gfn310. Epub 2008 Jun 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanthanum Carbonate	Other / unclassified	—	—

Indications